
Jubilant Pharma wins over Bracco’s Legal appeals in the United States Court of Appeals
Jubilant Pharma Limited (“Jubilant”), a subsidiary of Jubilant Pharmova Limited, announced that it has received a favorable and unanimous judgment from the United States Court of Appeals summarily affirming Jubilant’s earlier favorable rulings from the US Patent Office (“PTAB”) and the US International Trade Commission (“ITC”). These two rulings by the Appellate Court deny the appeals filed by Bracco Diagnostics, Inc (“Bracco”).

Jubilant successfully challenged Bracco’s patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office as well as in a separate proceeding in the ITC. In both instances, Jubilant was successful.
Despite the rulings of both the PTAB and the ITC, Bracco filed appeals to the US Court of Appeals in Washington D.C. These appeals are now dismissed.
“The rulings demonstrate the uniqueness of our RUBY-FILL Generator and Elution system and its intellectual property and the strength of our research and development efforts” commented Sergio Calvo, President of Jubilant’s Radiopharmaceuticals Division.
“The favorable ruling by the United States Court of Appeals further confirms Jubilant’s right to continue development and commercialization of RUBY-FILL® in the U.S. marketplace and to continue focusing on our goal of bringing innovative products to the market for patients in need of the latest technology,” stated Pramod Yadav, CEO, Jubilant Pharma Limited.
Shares of Jubilant Pharmova Limited was last trading in BSE at Rs.836 as compared to the previous close of Rs. 837.4. The total number of shares traded during the day was 8057 in over 535 trades.
The stock hit an intraday high of Rs. 846.3 and intraday low of 826.75. The net turnover during the day was Rs. 6720890
About Post Author
The India Wire Team
Related
More Stories
Jayanti Dalmia inaugrates 19th chapter of Flo at Vadodara.
The FICCI Ladies Organisation (FLO) 19th Chapter “FLO Vadodara” was launched on Saturday, by Jayanti Dalmia, the 39th President of...
Alembic reports 11% growth in revenue for Q4 FY22 from INR 1280 Cr. in FY21 to INR 1416 Cr.
Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 31st March 2022. Financial HighlightsIndia Branded Business up...
Vadodara based female entrepreneur launches India’s first eco friendly products e commerce portal zeroite.com
ZEROITE-THE ECO SPACE IS GUJARAT’S FIRST ZERO WASTE operational in Vadodara, city of Gujarat for last 2 years.Zeroite on the...
Alembic Pharmaceuticals announces its wholly owned subsidiary, Aleor Dermaceuticals Limited receives USFDA Final Approval for Clobetasol Propionate Foam.
Alembic Pharmaceuticals Limited (Alembic) today announced that its wholly owned subsidiary, Aleor Dermaceuticals Limited (Aleor) has received final approval from the...
Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets
Alembic Pharmaceuticals receives USFDA Tentative Approval for Ivabradine Tablets, 5 mg and 7.5 mg.Alembic Pharmaceuticals Limited (Alembic) today announced that...
IndiGo ranked 6th largest carrier in the world by passenger volume in OAG Frequency & Capacity Statistics for March 2022
India’s leading carrier - IndiGo has been ranked the 6th largest airline by passenger volume in the OAG Frequency & Capacity...
Average Rating